

Chemplast Sanmar

BSE SENSEX

52,266

S&P CNX

15,557

CMP: INR453
Unrated

Motilal Oswal values your support in the Asiamoney Brokers Poll 2022 for India Research, Sales, Corporate Access and Trading team. We [request your ballot.](#)



Financials Snapshot (INR b)

Y/E March	FY20	FY21	FY22
Sales	31.2	38.0	58.9
EBITDA	4.0	9.6	12.0
PAT	(1.3)	4.2	6.5
EPS (INR)	(6.6)	20.7	28.6
EPS Gr. (%)	(149.2)	(416.3)	38.0
BV/Sh.(INR)	84.7	(17.2)	75.2
Ratios			
Net D:E	1.1	(4.2)	(0.1)
RoE (%)	(6.2)	61.4	95.7
RoCE (%)	(5.7)	15.8	31.4
Payout (%)	-	-	-
Valuations			
P/E (x)	(69.0)	21.8	15.8
P/BV (x)	5.3	(26.2)	6.0
EV/EBITDA (x)	27.8	11.1	8.4
Div. Yield (%)	-	-	-
FCF Yield (%)	1.3	11.1	8.3

Integration at the forefront

Key highlights from the plant visit

Chemplast Sanmar, the largest manufacturer of Specialty Paste PVC resin India, via its wholly owned subsidiary - Chemplast Cuddalore Vinyls Ltd (CCVL) is the second largest manufacturer of Suspension PVC (S-PVC) in India. It has four manufacturing facilities (all in South India) with a high degree of backward integration.

We visited the company's Mettur facility, wherein it manufactures Refrigerant gases, Specialty Paste PVC Resin, Caustic Soda, Chlorinated Solvents, and Hydrogen Peroxide. Below are the key takeaways:

Physical proximity to key customers

- The Mettur plant of the company is located close to the Mettur Dam or the Stanley Reservoir, which is one of the largest dams in India. The plant has a capacity of 93.5TMC ft. The dam power house and the tunnel power house have a capacity of 40MW and 200MW, respectively.
- CHEMPLAST has four facilities in Mettur with each plant being managed by a separate plant manager. The four facilities are spread over 330 acres, with Plant 1 being 70-80 acres, Plants 2 & 3 being 80-90 acres each, and Plant 4 makes up for the remaining.
- Plant 3 is the oldest plant (commissioned in 1965) of the company wherein Caustic Soda, Chlorine, and Chlorinated Solvents are manufactured, followed by Plant 2 (1967) where Specialty Paste PVC Resin is manufactured, Plant 1 (1988) in which Refrigerant Gases are manufactured, and Plant 4 (2019) which manufactures Hydrogen Peroxide.
- The company also has a coal power plant with a capacity of 48.5MW, sufficient to supply power to all its plants in its Mettur location. CHEMPLAST uses 700-800tn/day of coal. The company imports a total of ~2.5L tonnes of coal from Indonesia. It imports a specific kind of coal having low ash and low sulphur content.
- While majority of the salt requirements are met through captive salt fields (~60%), the remaining is procured from Gujarat or from Southern India. The company also has a Zero Liquid Discharge facility that was commissioned in CY08 with a capacity of 2039KLPD with Aquatech technology. This capacity is more than adequate to meet the existing scale of operations and also for further expansions

Ambitious future prospects

- The current capacity of all the plants in the Mettur location stands at 204ktpa with another 52ktpa of Caustic Soda capacity in its Karaikal location. Suspension PVC resin capacity stands at 300ktpa with another 1068mtpa capacity for its custom manufacturing division.

Swarnendu Bhushan- Research Analyst (Swarnendu.Bhushan@MotilalOswal.com)

Shubham Mittal - Research Analyst (Shubham.Mittal@motilalosal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilalosal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

- Expansion plans are in place for the company in Suspension PVC, Paste PVC, and Custom Manufacturing. The company added 31ktpa capacity of S-PVC through debottlenecking in FY23.
- Specialty Paste PVC Resin plant was commissioned in 1967 with BF Goodrich Inc, USA. The current capacity of the plant stands at 66ktpa. CHEMPLAST produces VCM, a raw material for manufacturing Paste PVC, in-house through EDC. The company is planning to add 41ktpa capacity at Cuddalore with an estimated capex of INR3.6b. CHEMPLAST has already received environmental clearance for it.
- In the Customer Manufacturing segment of the business, CHEMPLAST has already commercialized 8 products with more in the pipeline that is likely to come online over the next 12 to 15 months. Pharma and Agrochem are its main end-user industries.
- This is a China +1 play for CHEMPLAST as customers are telling the company to be the supplier of choice.
- The company is setting up a multipurpose facility (block 1&2) in phases with the phase 1 expected to come online in 1HFY24 (capex of INR2.5b). The management expects the plant to be ready for full utilization by FY25.

Other key highlights

- Except for Caustic Soda, all the products of the company are currently sold at the spot rate and the management is working out a way to sell that on spot too
- As compared to the other plants, the Caustic Soda plant is power intensive in nature.
- Typically, 1.6tn of EDC produces 1tn of VCM, which in turn produces close to 1tn of Specialty Paste PVC resin.
- Mitsubishi in Japan is the largest trader of VCM in the world and CCVL sources all its VCM requirements from them. CHEMPLAST also plans to source the required VCM for the expanded capacity of 41kt from Mitsubishi.
- While CHEMPLAST produces Paste PVC by using the micro suspension technology, Finolex uses the emulsion technology. As per the management, demand for the micro suspension produced Paste PVC is more than the emulsion-based Paste PVC.
- India is a Paste PVC deficit market with annual demand at 145kt and the market growing by over 9% per annum.

Financial Story in Charts

Exhibit 1: Consolidated revenues have registered a CAGR of 13% over FY17-22




Exhibit 2: ...with EBITDAM at 20% in FY22 v/s 15% in FY17




Exhibit 3: Adjusted PAT has registered a CAGR of 30% in the past 5 years




Exhibit 4: ...with return profile also recovering after a blip in FY20




Exhibit 5: Strong FCF generation, cumulative of INR39b over FY17-22




Exhibit 6: ...CHEMPLAST turned net cash after its IPO in FY22 on a consolidated basis




Exhibit 7: Quarterly snapshot of the past 2 years

(INR m)

Y/E March	FY21				FY22				FY21	FY22	YoY (%)	QoQ (%)
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q				
Gross Sales	4,474	9,248	10,862	13,403	9,599	16,709	14,498	18,047	37,987	58,920	35%	24%
YoY Change (%)	NA	NA	NA	NA	114.6	80.7	33.5	34.6		55.1		
Gross Margins (%)	54%	46%	43%	41%	38%	36%	43%	33%	44%	37%	-7%	-9%
EBITDA	1,068	2,317	2,807	3,423	1,507	3,444	3,509	3,442	9,615	11,968	1%	-2%
Margins (%)	23.9	25.1	25.8	25.5	15.7	20.6	24.2	19.1	25.3	20.3	-6.5	-5.1
Depreciation	309	317	330	355	308	331	330	402	1,311	1,371		
Interest	1,070	1,213	1,135	916	1,004	1,489	374	349	4,334	3,216		
Other Income	-29	40	52	101	144	239	150	111	164	575		
PBT before EO expense	-341	828	1,394	2,253	338	1,862	2,954	2,801	4,134	7,955	24%	-5%
Extra-Ord expense	-47	-134	23	0	0	0	0	0	-157	0		
PBT	-388	694	1,418	2,253	338	1,862	2,954	2,801	3,977	7,955	24%	-5%
Tax	-506	-64	774	1,165	50	349	586	485	1,369	1,469		
Rate (%)	130.5	-9.2	54.6	51.7	14.8	18.7	19.8	17.3	34.4	18.5		
Minority Interest & P/L of Asso. Cos.	-1,185	-1,011	1,112	2,577	0	0	0	0	1,493	0		
Reported PAT	-1,066	-253	1,756	3,664	288	1,513	2,369	2,316	4,101	6,486	-37%	-2%
Adj PAT	-1,019	-120	1,733	3,664	288	1,513	2,369	2,316	4,258	6,486	-37%	-2%
YoY Change (%)	NA	NA	NA	NA	-128.3	-1,363.3	36.7	-36.8		52.3		
Margins (%)	-22.8	-1.3	15.9	27.3	3.0	9.1	16.3	12.8	11.2	11.0	-14.5	-3.5
Segment Revenue (INR m)												
Specialities	1,132	3,552	4,068	4,136	3,119	5,345	5,171	6,486	12,887	20,122	57%	25%
Commodity	3,291	5,713	6,817	9,286	6,488	11,388	9,350	11,603	25,107	38,828	25%	24%
Segment EBIT (INR m)												
Specialities	(675)	121	465	644	236	738	1,695	1,667	556	4,336	159%	-2%
Commodity	335	706	929	1,609	102	1,124	1,259	1,134	3,578	3,619	-29%	-10%

Sources: Company, MOFSL


Exhibit 8: Financial summary

(INR b)

Y/E March	FY17	FY18	FY19	FY20	FY21	FY22
Sales	32.6	31.9	33.0	31.2	38.0	58.9
EBITDA	4.8	5.4	5.2	4.0	9.6	12.0
PAT	1.7	2.4	2.7	(1.3)	4.2	6.5
EPS (INR)	8.5	11.8	13.3	(6.6)	20.7	28.6
EPS Gr. (%)		37.6	13.3	(149.2)	(416.3)	38.0
BV/Sh.(INR)	15.7	9.8	125.1	84.7	(17.2)	75.2
Ratios						
Net D:E	1.1	1.8	0.1	1.1	(4.2)	(0.1)
RoE (%)	109.2	92.4	19.7	(6.2)	61.4	95.7
RoCE (%)	50.8	32.9	15.4	(5.7)	15.8	31.4
Payout (%)	-	-	-	-	-	-
Valuations						
P/E (x)	52.9	38.5	33.9	(69.0)	21.8	15.8
P/BV (x)	28.9	46.1	3.6	5.3	(26.2)	6.0
EV/EBITDA (x)	19.9	17.8	18.1	27.8	11.1	8.4
Div. Yield (%)	-	-	-	-	-	-
FCF Yield (%)	6.5	5.9	8.6	1.3	11.1	8.3

Sources: Company, MOFSL

Exhibit 9: Overall realization has grown at a steady pace over the past eight quarters




Source: Company, MOFSL

Exhibit 10: The three segments of the company

	Chemplast Sanmar					CCVL ⁽¹⁾
	Specialty Chemicals		Non-Specialty Chemicals			Suspension PVC
End user industries	Specialty Paste PVC resin Footwear Auto upholstery	Custom manufacturing Pharma Agrochemicals	Caustic soda Paper Textile	Hydrogen peroxide Paper & Pulp Textile Park	Chloromethanes Pharma	 Irrigation
	 Leather Mats API Molecules Chemicals	 Chemicals Effluent treatment at refineries Disinfectants	 Agro-Chemicals Refrigerants (HFOs)	 Urban infra	 Real estate	
Capacity	66,000 mtpa	1,068 mtpa	119,000 mtpa	34,000 ⁽²⁾ mtpa	35,000 mtpa	300,000 mtpa
FY22 Sales split	22%		12%			66%

Sources: Company, MOFSL


Exhibit 11: High degree of backward integration at both the plant locations



Source: Company, MOFSL

Exhibit 12: Aggressive expansion plans in place with a strong product pipeline till FY25

Low cost future expansion leveraging existing land and infrastructure facilities



*S-PVC debottlenecking has already been completed in 1QFY23

Source: Company, MOFSL

Exhibit 13: CHEMPLAST enjoys proximity to key customers across industries in South and East India

Location	Chemplast Sanmar			CCVL	
	Mettur, Tamilnadu	Berigai Tamilnadu	Karaikal, Puducherry	Cuddalore, Tamilnadu	
Capacity	Paste PVC	66 ktpa	Custom manufacturing 1068 mtpa	Caustic soda 52 ktpa	Suspension PVC resin 300 ktpa
	Caustic Soda	67 ktpa			
	Hydrogen Peroxide	34 ktpa			
	Chloromethanes	35 ktpa			
	Refrigerant gas	1.7 ktpa			
Key highlights	<ul style="list-style-type: none"> Zero liquid discharge facility Sourcing of power from a captive power plant of 48.5 MW Leased salt field to ensure stable supply 	<ul style="list-style-type: none"> Multi-purpose facility Fully automated with distributed control systems and modern technologies Capability to support development work in various chemistries at the laboratory scale and pilot scale 	<ul style="list-style-type: none"> Zero liquid discharge plant Desalination plant Captive terminal for import of feedstock and sale of product Two captive power plants of 8.5 MW and 3.5 MW Stores ethylene in a double walled insulated cryogenic tank with 4 kt capacity Leased salt field to ensure stable supply 	<ul style="list-style-type: none"> Zero liquid discharge plant Desalination plant Captive terminal for import of feedstock Has two refrigerated atmospheric storage tanks with a capacity of 7,500 MT each for VCM Debottlenecking of capacity by 31kt is underway 	
	ISO 14001 2015	✓	✓	✓	✓
ISO 9001 2015	✓	✓	✓	✓	
ISO 45001 2015	✓	✓	✓	✓	

Source: Company, MOFSL

Exhibit 14: Sneak peek into the manufacturing facilities of CHEMPLAST



Paste PVC plant, Mettur, Tamilnadu



Chloromethanes plant, Mettur, Tamilnadu



Custom manufacturing, Berigai, Tamilnadu



Custom manufacturing, Berigai, Tamilnadu



Caustic Soda manufacturing, Karaikal, Puducherry



Suspension PVC, Cuddalore, Tamilnadu

Source: Company, MOFSL

Financials and Valuations

Consolidated - Financial Snapshot						(INR m)
Y/E March	FY17	FY18	FY19	FY20	FY21	FY22
Total Income from Operations	32,620	31,893	33,050	31,228	37,987	58,920
Change (%)		-2.2	3.6	-5.5	21.6	55.1
Gross Margins (%)	45.6	41.7	39.1	38.1	44.1	37.0
EBITDA	4,794	5,358	5,187	4,004	9,615	11,968
Margin (%)	14.7	16.8	15.7	12.8	25.3	20.3
Depreciation	687	810	793	1,291	1,311	1,371
EBIT	4,106	4,547	4,394	2,713	8,304	10,597
Int. and Finance Charges	726	775	1,108	2,119	4,334	3,216
Other Income	290	241	248	192	164	575
PBT bef. EO Exp.	3,671	4,013	3,534	786	4,134	7,955
EO Items	-486	-277	151	-1,069	-157	0
PBT after EO Exp.	3,185	3,737	3,685	-283	3,977	7,955
Total Tax	1,682	1,518	869	-509	1,369	1,469
Tax Rate (%)	52.8	40.6	23.6	180.2	34.4	18.5
Minority Interest	0	0	0	698	-1,493	0
Reported PAT	1,502	2,219	2,816	-472	4,101	6,486
Adjusted PAT	1,732	2,383	2,700	-1,329	4,204	6,486
Change (%)		37.6	13.3	-149.2	-416.3	54.3
Margin (%)	5.3	7.5	8.2	-4.3	11.1	11.0

Consolidated - Balance Sheet						(INR m)
Y/E March	FY17	FY18	FY19	FY20	FY21	FY22
Equity Share Capital	800	33,639	33,639	25,567	1,014	1,134
Total Reserves	2,373	-31,651	-8,276	-8,389	-4,509	15,917
Net Worth	3,173	1,988	25,363	17,178	-3,495	17,050
Total Loans	4,270	5,245	3,361	21,429	21,102	8,674
Deferred Tax Liabilities	721	1,863	8,157	6,751	7,200	7,415
Capital Employed	8,164	9,096	36,881	45,358	24,807	33,139
Gross Block	11,348	12,210	32,199	33,849	34,320	36,802
Less: Accum. Deprn.	681	1,511	276	1,530	2,841	4,212
Net Fixed Assets	10,666	10,699	31,923	32,320	31,479	32,590
Capital WIP	61	818	1,193	127	251	337
Total Investments	6,078	9,383	11,994	26,435	0	0
Curr. Assets, Loans&Adv.	5,917	13,583	9,883	7,452	13,135	23,083
Inventory	3,296	3,318	3,877	3,198	4,071	7,110
Account Receivables	735	694	719	501	739	1,898
Cash and Bank Balance	622	1,629	1,025	1,799	6,513	10,227
Cash	622	1,532	991	922	3,035	9,998
Bank Balance	0	38	34	877	3,478	2,294
Loans and Advances	1,264	7,942	4,262	1,954	1,812	3,847
Curr. Liability & Prov.	14,558	25,388	18,112	20,975	20,058	22,871
Account Payables	10,679	9,637	13,609	13,972	16,561	18,783
Other Current Liabilities	3,879	15,751	4,503	7,004	3,496	4,088
Net Current Assets	-8,641	-11,805	-8,229	-13,523	-6,923	212
Appl. of Funds	8,164	9,095	36,881	45,359	24,808	33,139

Financials and Valuations

Ratios

Y/E March	FY17	FY18	FY19	FY20	FY21	FY22
Basic (INR)						
EPS	8.5	11.8	13.3	-6.6	20.7	28.6
EPS Growth (%)		37.6	13.3	-149.2	-416.3	38.0
Cash EPS	11.9	15.8	17.2	-0.2	27.2	34.7
BV/Share	15.7	9.8	125.1	84.7	-17.2	75.2
Valuation (x)						
P/E	52.9	38.5	33.9	-69.0	21.8	15.8
Cash P/E	37.9	28.7	26.2	-2,385.0	16.6	13
P/BV	28.9	46.1	3.6	5.3	-26.2	6
EV/Sales	2.9	3.0	2.8	3.6	2.8	2
EV/EBITDA	19.9	17.8	18.1	27.8	11.1	8
FCF per share	29.5	26.5	38.8	6.0	50.4	37
Return Ratios (%)						
RoE	109.2	92.4	19.7	-6.2	61.4	95.7
RoCE	50.8	32.9	15.4	-5.7	15.8	31
RoIC	276.1	-405.6	33.7	-11.0	31.1	43
Working Capital Ratios						
Fixed Asset Turnover (x)	6.1	3.0	1.6	1.0	1.2	1.8
Asset Turnover (x)	4.0	3.5	0.9	0.7	1.5	1.8
Inventory (Days)	37	38	43	37	39	44
Debtor (Days)	8	8	8	6	7	12
Creditor (Days)	119	110	150	163	159	116
Leverage Ratio (x)						
Current Ratio	0.4	0.5	0.5	0.4	0.7	1.0
Interest Cover Ratio	5.7	5.9	4.0	1.3	1.9	3.3
Net Debt/Equity	1.1	1.8	0.1	1.1	-4.2	-0.1

Consolidated - Cash Flow Statement

Y/E March	FY17	FY18	FY19	FY20	FY21	FY22
(INR m)						
OP/(Loss) before Tax	3,671	4,015	3,534	88	5,627	7,955
Depreciation	687	1,051	793	1,291	1,311	1,371
Interest Expenses	726	1,176	1,108	2,119	4,334	3,216
Others	-469	1,258	186	-379	-382	-385
Direct Taxes Paid	-588	-713	-824	-424	-605	-1,736
(Inc)/Dec in WC	2,389	-829	3,737	-839	480	-1,412
CF from Operations	6,416	5,957	8,535	1,856	10,764	9,010
(Inc)/Dec in FA	-444	-585	-662	-642	-545	-521
Free Cash Flow	5,971	5,372	7,873	1,214	10,218	8,489
Change in Investments	-3,649	-29,848	-5,766	-12,414	24,553	1,294
Others	217	108	115	-739	-2,493	308
CF from Investments	-3,876	-30,325	-6,313	-13,795	21,515	1,082
Issue of Shares	0	3,000	0	0	0	12,822
Inc/(Dec) in Debt	-2,765	25,585	-1,711	19,521	-1,672	-12,898
Interest Paid	-732	-1,521	-1,111	-2,565	-3,896	-3,006
Others	0	0	0	-5,087	-24,599	-46
CF from Fin. Activity	-3,497	27,063	-2,822	11,869	-30,166	-3,129
Inc/Dec of Cash	-957	2,695	-600	-69	2,113	6,963
Opening Balance	1,579	-1,163	1,591	991	922	3,035
Closing Balance	622	1,532	991	922	3,035	9,997

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Investment Advisory Services, Depository participant services & distribution of various financial products. MOFSL is a subsidiary company of Passionate Investment Management Pvt. Ltd.. (PIMPL). MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co.Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. As per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

Specific Disclosures

- 1 MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3 MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- 5 Research Analyst has not served as director/officer/employee in the subject company
- 6 MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- 7 MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8 MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- 9 MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company
- received compensation/other benefits from the subject company in the past 12 months
- other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 71934200/ 022-71934263; Website www.motilaloswal.com CIN no.: L67190MH2005PLC153397. Correspondence Office Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad(West), Mumbai- 400 064. Tel No: 022 7188 1000.

Registration Nos.: Motilal Oswal Financial Services Limited (MOFSL)*: INZ000158836(BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412. AMFI: ARN - 146822; Investment Adviser: INA000007100; Insurance Corporate Agent: CA0579;PMS:INP000006712. Motilal Oswal Asset Management Company Ltd. (MOAMC): PMS (Registration No.: INP00000670); PMS and Mutual Funds are offered through MOAMC which is group company of MOFSL. Motilal Oswal Wealth Management Ltd. (MOWML): PMS (Registration No.: INP000004409) is offered through MOWML, which is a group company of MOFSL. Motilal Oswal Financial Services Limited is a distributor of Mutual Funds, PMS, Fixed Deposit, Bond, NCDs, Insurance Products and IPOs. Real Estate is offered through Motilal Oswal Real Estate Investment Advisors II Pvt. Ltd. which is a group company of MOFSL. Private Equity is offered through Motilal Oswal Private Equity Investment Advisors Pvt. Ltd which is a group company of MOFSL. Research & Advisory services is backed by proper research. Please read the Risk Disclosure Document prescribed by the Stock Exchanges carefully before investing. There is no assurance or guarantee of the returns. Investment in securities market is subject to market risk, read all the related documents carefully before investing. Details of Compliance Officer: Name: Neeraj Agarwal, Email ID: na@motilaloswal.com, Contact No.:022-71881085.

* MOSL has been amalgamated with Motilal Oswal Financial Services Limited (MOFSL) w.e.f August 21, 2018 pursuant to order dated July 30, 2018 issued by Hon'ble National Company Law Tribunal, Mumbai Bench.